Literature DB >> 9657575

Expression of insulin-like growth factors and their binding proteins by bronchoalveolar cells from children with and without interstitial lung disease.

K Chadelat1, M Boule, S Corroyer, B Fauroux, B Delaisi, G Tournier, A Clement.   

Abstract

The involvement of the insulin-like growth factor (IGF) system in lung growth and repair following injury is sustained by a number of studies. Based on this knowledge, the aim of the present work was to document the expression of the IGFs and their binding proteins by alveolar cells obtained by bronchoalveolar lavage (BAL). Two groups were investigated: a control group of five children and a group of 11 children referred to the department for exploration of interstitial lung disease (ILD). Components of the IGF system studied included IGF-I, IGF-II and IGF-binding proteins (IGFBP). Expression of these factors was analysed at the level of messenger ribonucleic acid (mRNA) (by semi-quantitative reverse transcription polymerase chain reaction techniques), and of protein for the IGFBPs. In addition, expression of two major cytokines associated with the inflammatory process, tumour necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta), was also documented. In children without parenchymal disease, the growth factor expressed was IGF-I, in association with the presence of mRNA for IGFBP-2 in all cases. In children with ILD, expression of IGF-I was observed in nine patients and of IGF-II in three patients, and the presence of IGFBP-2 was found in all extracts analysed (mRNA and proteins). Evaluation of IGFBP-2 expression indicated an increase in the group of children with ILD. Interestingly, a significant association was observed between the increase in IGFBP-2 expression and TGF-beta expression. The present data emphasize the presence on insulin-like growth factor-binding protein-2 in the BAL of all patients, and suggest that this protein may be an important factor of the injury/repair processes during the progression of alveolar inflammation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657575     DOI: 10.1183/09031936.98.11061329

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  4 in total

1.  Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.

Authors:  Julien Guiot; Makon-Sébastien Njock; Béatrice André; Fanny Gester; Monique Henket; Dominique de Seny; Catherine Moermans; Michel G Malaise; Renaud Louis
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

Review 2.  Growth factors in idiopathic pulmonary fibrosis: relative roles.

Authors:  Jeremy T Allen; Monica A Spiteri
Journal:  Respir Res       Date:  2001-11-28

3.  Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7.

Authors:  J Guiot; M Henket; J L Corhay; C Moermans; R Louis
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

4.  Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.

Authors:  J Guiot; B Bondue; M Henket; J L Corhay; R Louis
Journal:  BMC Pulm Med       Date:  2016-05-23       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.